Crinetics Pharmaceuticals, Inc. (CRNX) Financial Statements

Executive TeamFinancials
Shareholders

Crinetics Pharmaceuticals financial statements at a glance

Crinetics Pharmaceuticals reported revenue of $7.70 million for fiscal year 2025 (ended December 31, 2025), up 640.7% from fiscal year 2024. Net income was -$465.32 million, a net margin of 6046.2% loss.

At the end of fiscal year 2025 it had total assets of $1.13 billion, total liabilities of $134.17 million and shareholders' equity of $992.08 million, with cash and short-term investments of $1.03 billion and total debt of $48.54 million.

Its operations brought in -$377.92 million of cash; capital spending was $5.76 million, leaving free cash flow of -$383.68 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

CRNX logo

Crinetics Pharmaceuticals, Inc.

CRNXUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
7.70M
Prev Year: 1.04M
YoY: +640.7%
Operating Revenue
7.70M
Prev Year: 1.04M
YoY: +640.7%
Cost of Revenue
1.08M
Gross Profit
6.62M
Operating Expense
523.39M
Prev Year: 339.89M
YoY: +54.0%
Selling General and Administrative
191.33M
Prev Year: 99.74M
YoY: +91.8%
General and Administrative Expense
191.33M
Prev Year: 99.74M
YoY: +91.8%
Other General and Administrative
191.33M
Prev Year: 99.74M
YoY: +91.8%
Research and Development
332.06M
Prev Year: 240.16M
YoY: +38.3%
Operating Income
-516.77M
Prev Year: -338.85M
YoY: -52.5%
Net Non Operating Interest Income Expense
51.99M
Prev Year: 41.44M
YoY: +25.5%
Non-operating Interest Income
51.99M
Prev Year: 41.44M
YoY: +25.5%
Other Income Expense
-357.0K
Prev Year: -989.0K
YoY: +63.9%
Other Non-operating Income (expense)
-357.0K
Prev Year: -519.0K
YoY: +31.2%
Pre-tax Income
-465.14M
Prev Year: -298.41M
YoY: -55.9%
Provision for Income Taxes
180.0K
Basic EPS
-
Prev Year: -3.69
Net Income Common Stockholders
-465.32M
Prev Year: -298.41M
YoY: -55.9%
Diluted EPS
-
Prev Year: -3.69
Net Income
-465.32M
Prev Year: -298.41M
YoY: -55.9%
Net Income Including Non-Controlling Interests
-465.32M
Prev Year: -298.41M
YoY: -55.9%
Net Income from Continuing Operations
-465.32M
Prev Year: -298.41M
YoY: -55.9%
Net Income from Continuing and Discontinued Operation
-465.32M
Prev Year: -298.41M
YoY: -55.9%
Weighted Average Shares (basic)
-
Prev Year: 80.78M
Normalized Income
-465.32M
Prev Year: -298.41M
YoY: -55.9%
Weighted Average Shares (diluted)
-
Prev Year: 80.78M
Interest Income
51.99M
Prev Year: 41.44M
YoY: +25.5%
Net Interest Income
51.99M
Prev Year: 41.44M
YoY: +25.5%
EBIT
-516.77M
Prev Year: -338.85M
YoY: -52.5%
EBITDA
-512.88M
Prev Year: -336.07M
YoY: -52.6%
Reconciled Cost of Revenue
1.08M
Interest Expense
-
Reconciled Depreciation
3.89M
Prev Year: 2.79M
YoY: +39.7%
Net Income from Continuing Operation Net Minority Interest
-465.32M
Prev Year: -298.41M
YoY: -55.9%
Normalized EBITDA
-512.88M
Prev Year: -336.07M
YoY: -52.6%
Tax Rate for Calcs
0.21
Total Expenses
524.47M
Prev Year: 339.89M
YoY: +54.3%
Total Unusual Items Excluding Goodwill
-
Total Operating Income as Reported
-516.77M
Prev Year: -338.85M
YoY: -52.5%
Total Unusual Items
-
Diluted NI Available to Com Stockholders
-465.32M
Prev Year: -298.41M
YoY: -55.9%
Values in USD

Crinetics Pharmaceuticals key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$7.7M$1.0M$4.0M$4.7M$1.1M
Gross profit$6.6M––––
Operating income-$516.8M-$338.9M-$222.6M-$167.9M-$107.7M
Net income-$465.3M-$298.4M-$214.5M-$163.9M-$107.6M
Diluted EPS–-$3.69-$3.69-$3.15-$2.80
Total assets$1.1B$1.4B$635.4M$352.2M$351.0M
Total liabilities$134.2M$109.8M$96.2M$35.8M$19.1M
Shareholders' equity$992.1M$1.3B$539.1M$316.3M$331.9M
Cash and short-term investments$1.0B$1.4B$558.6M$334.4M$333.7M
Total debt$48.5M$51.7M$51.7M$3.1M$3.1M
Operating cash flow-$377.9M-$226.0M-$166.3M-$115.2M-$88.6M
Capital spending$5.8M$3.8M$4.7M$1.7M$436,000
Free cash flow-$383.7M-$229.8M-$171.0M-$116.9M-$89.0M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2016.

Questions and answers

What was Crinetics Pharmaceuticals's revenue in fiscal year 2025?

$7.70 million, up 640.7% from $1.04 million in fiscal year 2024.

How much profit does Crinetics Pharmaceuticals make?

Crinetics Pharmaceuticals reported net income of -$465.32 million for fiscal year 2025 (6046.2% of revenue); operating income was -$516.77 million.

How much cash and debt does Crinetics Pharmaceuticals have?

At the end of fiscal year 2025: cash and short-term investments of $1.03 billion and total debt of $48.54 million.

What is Crinetics Pharmaceuticals's free cash flow?

-$383.68 million in fiscal year 2025 (operating cash flow of -$377.92 million minus capital spending of $5.76 million).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube